Pathogenesis and possible therapies modelled in ovine Batten disease

绵羊巴顿病的发病机制和可能的治疗方法

基本信息

  • 批准号:
    7277623
  • 负责人:
  • 金额:
    $ 26.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-08-16 至 2009-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The neuronal ceroid lipofuscinoses (NCLs, Batten disease) are devastating inherited fatal neurodegenerative diseases of children. At present there are no effective therapies and palliative care is difficult. Studies on a CLN6 form in New Zealand sheep have proved invaluable in understanding the biochemistry and preclinical pathology. These sheep have a human-like brain anatomy, physiology and genetic organization, and display similar neuropathology dominated by cortical atrophy, and a similar development of clinical disease. The overall aim of this project is to complete understanding to a point where in vivo trials of viral vector gene therapies can begin. Molecular biology, biochemistry and immunohistological experiments will define the gene product required for correction and its subcellular site of residence. Neuron cultures will be be tested with lenti- and adeno-associated virally derived vectors to determine suitability for transduction of the gene into sheep neurons and glial cells. Prenatal and preclinical neuropathology studies indicated that glial activation has a primary role in the pathogenesis of this disease. Further studies will define the cascade of glial cell activation and inflammation, to determine the critical steps and thus determine the most effective point for intervention. The effectiveness of chronic treatment with anti-inflammatory drugs on the development of the disease in sheep will be tested in vivo. Prolonged neurogenesis and migration of cells from the subventricular zone to the affected areas in the brains of affected sheep was also indicated in the pathology studies. The extent of this will be established by BrdU labeling of new cells in vivo and antibody detection. Finally the usefulness of this migration for carrying a gene in viral vectors to the areas where it is required will be determined by targeted injection of the preferred vector carrying a reporter gene into affected sheep brains and detection of the dispersal of gene expression. These studies are aimed at providing all the requirements for directly testing gene therapy on the sheep, in combination with suppression of inflammation. The target cells will have been identified along with the CLN6 gene product relevant to them. The time window for therapy will have been defined along with the role of suppression of inflammation in slowing the course of the disease. The most effective viral vector will have been identified and the techniques for injection into the SVZ established. REVELANCE: This project intends to gain knowledge to define realistic therapies in a large animal form of Batten disease that can be tested for possible human use. Much of the knowledge gained will be relevant to other diseases and other treatment strategies, such as Alzheimer's disease and stem cell transplantation.
描述(申请人提供):神经性蜡样脂褐素增多症(NCLS,巴顿病)是一种毁灭性的遗传性儿童致死性神经退行性疾病。目前还没有有效的治疗方法,姑息治疗也很困难。对新西兰绵羊的CLN6形式的研究已被证明对理解生物化学和临床前病理有非常重要的价值。这些绵羊具有与人类相似的大脑解剖、生理和遗传组织,并表现出类似的以皮质萎缩为主导的神经病理,以及类似的临床疾病发展。这个项目的总体目标是完全理解到可以开始病毒载体基因疗法的体内试验的程度。分子生物学、生物化学和免疫组织学实验将确定矫正所需的基因产物及其亚细胞居留位置。神经元培养将用Lenti和腺相关病毒衍生载体进行测试,以确定是否适合将该基因转导到绵羊神经元和神经胶质细胞。产前和临床前的神经病理学研究表明,神经胶质细胞的激活在本病的发病机制中起主要作用。进一步的研究将确定胶质细胞激活和炎症的级联反应,以确定关键步骤,从而确定最有效的干预点。抗炎药物慢性治疗对绵羊疾病发展的有效性将在体内进行测试。病理学研究还表明,绵羊脑室下区的神经发生和细胞迁移到患区的时间延长。这一程度将通过体内新细胞的BrdU标记和抗体检测来确定。最后,通过将携带报告基因的首选载体定向注射到受影响的绵羊大脑中,并检测基因表达的扩散,将确定这种将病毒载体中的基因转移到所需区域的有用性。这些研究的目的是为在绵羊身上直接测试基因疗法以及抑制炎症提供所有要求。靶细胞将与与它们相关的CLN6基因产物一起被鉴定。治疗的时间窗口将与抑制炎症在减缓疾病进程中的作用一起确定。最有效的病毒载体将被确定,注射到SVZ的技术将被建立。Revelance:这个项目旨在获得知识,以确定一种大型动物形式的巴顿病的现实治疗方法,该方法可以测试为可能的人类使用。获得的大部分知识将与其他疾病和其他治疗策略相关,如阿尔茨海默病和干细胞移植。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID N PALMER其他文献

DAVID N PALMER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID N PALMER', 18)}}的其他基金

Pathogenesis and possible therapies modelled in ovine Batten disease
绵羊巴顿病的发病机制和可能的治疗方法
  • 批准号:
    7144375
  • 财政年份:
    2006
  • 资助金额:
    $ 26.84万
  • 项目类别:
Pathogenesis and possible therapies modelled in ovine Batten disease
绵羊巴顿病的发病机制和可能的治疗方法
  • 批准号:
    7383875
  • 财政年份:
    2006
  • 资助金额:
    $ 26.84万
  • 项目类别:
NEURON CULTURES FOR CLN6 BATTEN DISEASE STUDIES
用于 CLN6 Batten 疾病研究的神经元培养物
  • 批准号:
    6448833
  • 财政年份:
    2000
  • 资助金额:
    $ 26.84万
  • 项目类别:
NEURON CULTURES FOR CLN6 BATTEN DISEASE STUDIES
用于 CLN6 Batten 疾病研究的神经元培养物
  • 批准号:
    6165291
  • 财政年份:
    2000
  • 资助金额:
    $ 26.84万
  • 项目类别:
NEURON CULTURES FOR CLN6 BATTEN DISEASE STUDIES
用于 CLN6 Batten 疾病研究的神经元培养物
  • 批准号:
    6660441
  • 财政年份:
    2000
  • 资助金额:
    $ 26.84万
  • 项目类别:
NEURON CULTURES FOR CLN6 BATTEN DISEASE STUDIES
用于 CLN6 Batten 疾病研究的神经元培养物
  • 批准号:
    6394484
  • 财政年份:
    2000
  • 资助金额:
    $ 26.84万
  • 项目类别:
NEURON CULTURES FOR CLN6 BATTEN DISEASE STUDIES
用于 CLN6 Batten 疾病研究的神经元培养物
  • 批准号:
    6529491
  • 财政年份:
    2000
  • 资助金额:
    $ 26.84万
  • 项目类别:
BATTEN DISEASE
板条病
  • 批准号:
    2270462
  • 财政年份:
    1994
  • 资助金额:
    $ 26.84万
  • 项目类别:
BATTEN DISEASE
板条病
  • 批准号:
    2270461
  • 财政年份:
    1994
  • 资助金额:
    $ 26.84万
  • 项目类别:
BATTEN DISEASE
板条病
  • 批准号:
    2037724
  • 财政年份:
    1994
  • 资助金额:
    $ 26.84万
  • 项目类别:

相似海外基金

Alternative splicing of Grin1 controls NMDA receptor function in physiological and disease processes
Grin1 的选择性剪接控制生理和疾病过程中的 NMDA 受体功能
  • 批准号:
    488788
  • 财政年份:
    2023
  • 资助金额:
    $ 26.84万
  • 项目类别:
    Operating Grants
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
RBFOX2 失调通过选择性剪接促进胰腺癌进展
  • 批准号:
    10638347
  • 财政年份:
    2023
  • 资助金额:
    $ 26.84万
  • 项目类别:
Long Noncoding RNA H19 Mediating Alternative Splicing in ALD Pathogenesis
长非编码 RNA H19 介导 ALD 发病机制中的选择性剪接
  • 批准号:
    10717440
  • 财政年份:
    2023
  • 资助金额:
    $ 26.84万
  • 项目类别:
Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma
使用蛋白质基因组学评估选择性剪接事件对胶质母细胞瘤的功能影响
  • 批准号:
    10577186
  • 财政年份:
    2023
  • 资助金额:
    $ 26.84万
  • 项目类别:
Alternative splicing regulation of CLTC in the heart
心脏中 CLTC 的选择性剪接调节
  • 批准号:
    10749474
  • 财政年份:
    2023
  • 资助金额:
    $ 26.84万
  • 项目类别:
Nitric oxide as a novel regulator of alternative splicing
一氧化氮作为选择性剪接的新型调节剂
  • 批准号:
    10673458
  • 财政年份:
    2023
  • 资助金额:
    $ 26.84万
  • 项目类别:
Alternative splicing as an evolutionary driver of phenotypic plasticity
选择性剪接作为表型可塑性的进化驱动力
  • 批准号:
    2884151
  • 财政年份:
    2023
  • 资助金额:
    $ 26.84万
  • 项目类别:
    Studentship
Rescuing SYNGAP1 haploinsufficiency by redirecting alternative splicing
通过重定向选择性剪接挽救 SYNGAP1 单倍体不足
  • 批准号:
    10660668
  • 财政年份:
    2023
  • 资助金额:
    $ 26.84万
  • 项目类别:
CAREER: Mechanotransduction, transcription, and alternative splicing in cell biology
职业:细胞生物学中的机械转导、转录和选择性剪接
  • 批准号:
    2239056
  • 财政年份:
    2023
  • 资助金额:
    $ 26.84万
  • 项目类别:
    Continuing Grant
Investigating the role of alternative splicing in the islets of Langerhans in developing diabetes.
研究朗格汉斯岛中选择性剪接在糖尿病发生中的作用。
  • 批准号:
    468851650
  • 财政年份:
    2022
  • 资助金额:
    $ 26.84万
  • 项目类别:
    Research Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了